AMAP102 is a novel, orally available compound for the treatment of rheumatoid arthritis, originated from AnaMar's proprietary 5-HT2 antagonists. The concept of using a 5-HT2 antagonist for the treatment of the inflammatory component in arthritis and inflammatory pain provides a unique and novel alternative to the established rheumatoid arthritis therapies.
The beneficial effects of AMAP102 have been shown in several disease models highly relevant to rheumatoid arthritis, including inflammatory pain. AMAP102 has been evaluated in a phase I clinical study, consisting of single ascending and multiple ascending oral dosing in healthy volunteers.
